Clinical trial
A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
NCT01142011 · Cancer Trials Australia, Other · Unknown status
Key facts
| NCT number | NCT01142011 |
|---|---|
| Title | A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia |
| Official title | A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia |
| Lead sponsor | Cancer Trials Australia, Other |
| Collaborators | Human Genome Sciences Inc. Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Symptomatic Waldenstroms Macroglobulinaemia |
| Intervention type | Drug |
| Interventions | Belimumab |
| Enrollment | 15 |
| Start date | Nov 1, 2009 |
| Primary completion | Jun 1, 2012 |
| Completion | Jan 1, 2013 |
| First posted | Jun 11, 2010 |
| Last update posted | Feb 10, 2012 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- 100–999 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: